Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the filing of a ...

Raanana, Israel - Polyrizon Ltd. (NASDAQ:PLRZ), a biotech firm in the development stage, has filed a divisional patent application in Israel for its Trap & Target (NYSE:TGT) (T&T) platform technology.

Polyrizon (PLRZ) announced the filing of a divisional patent application with the Israel Patent Office for its Trap & Target platform ...

Biopharmaceutical Drug Delivery Technologies Market The global biopharmaceutical drug delivery technologies <a target=_blank href=https: ...

Oversubscribed Seed Round Accelerates Nasdepi®'s Journey as the First Dry Powder Nasal, Heat-Stable Treatment for Anaphylaxis RALEIGH, NORTH CAROLINA / ACCESS Newswire / January 21, 2025 / Belhaven ...

RALEIGH, NORTH CAROLINA / ACCESS Newswire / January 21, 2025 / Belhaven Biopharma, a leader in dry powder nasal drug delivery systems, announces the launch of a new clinical study designed to ...

A novel approach developed by scientists, including Rice University chemist James Tour, could transform treatment for ...

a leader in dry powder nasal drug delivery systems, announces the launch of a new clinical study designed to evaluate the commercial dose of Nasdepi ®, an epinephrine product for intranasal ...

MDR Certification Strengthens Resyca's Leadership in Soft Mist Drug-Device Combination Products ENSCHEDE, NL / ACCESS Newswire / January 28, 2025 / Resyca BV, a pioneering leader in the development an ...

The HSE has indicated that local services will continue to monitor the drugs market in Cork over the weekend to identify if ...

Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed strong safety and efficacy, with plans for a phase 2 trial in 2025.